Establishing the Criteria in Repeated Usage of Traditional Chinese Patent Medicines by Modified Delphi
ZHU Hao-ru1,2, YAN Ying-ying1, ZHENG Hu-zhan2, YANG Yi-heng1*
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China; 2. Department of Clinical Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100029, China
Abstract��OBJECTIVE To establish the criteria in repeated usage of traditional Chinese patent medicines. METHODS Fifteen experts were invited to take a two-rounded questionnaire survey. Experts' positive coefficients, authority coefficient, reliability, concentration degree and coordination degree towards experts' opinions were calculated by SPSS23.0 after integrating the opinions. The criteria were modified based on the prespecified principles. RESULTS In this two-rounded survey, experts' positive coefficients were 100.00% and 93.33%, averaging authority coefficient was 0.91, reliability of two rounds were 0.87 and 0.82. Coordination degree increased from 0.36 (P<0.01) to 0.46 (P<0.01). Three first level index and eighteen second level index were included in this cirteria. CONCLUSION With well response, authority, reliability and coordination, this study could define preliminary evaluation criteria of repeated traditional Chinese patent medicines.
�����, ��ӯӯ, ֣��ռ, �����. �Ľ��¶��Ʒ������г�ҩ�ظ���ҩ���۱�[J]. �й�ҩѧ��־, 2017, 52(20): 1867-1871.
ZHU Hao-ru, YAN Ying-ying, ZHENG Hu-zhan, YANG Yi-heng. Establishing the Criteria in Repeated Usage of Traditional Chinese Patent Medicines by Modified Delphi. Chinese Pharmaceutical Journal, 2017, 52(20): 1867-1871.
WANG Y G, LI H Y, KONG X W, et al. Exploration of the key factors for clinical rational use of Chinese patent medicine based on prescription evaluation [J]. J China Pharm(�й�ҩ��), 2014, 25(11):970-969.
[2]
JIN R, WANG Y G, XUE C M, et al. The exploration on the creteria and compromise of prescription review of Chinese patent medicines I:the overdose medication [J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2015, 35(6):473-477.
[3]
NHFPC. Management Practices of Hospital Prescription Comment(Trial)[EB/OL]. (2010)[2017-04-11]. http://www.nhfpc.gov.cn/yzygj/s3590/201003/ac4d04a85da5478793761224abc10fd3.shtml.
[4]
BMHB. The Guidance of Special Comments on Prescription in Beijing Medical Institutions (Trial)[S].(2012)[2017-04-11]. http://www.moh.gov.cn/zwgkzt/s9968/201212/f76fcb555824429195c131efc24372d2.shtml.
[5]
SATCM. Guidance for Clinical Application of Chinese Patent Medicine [EB/OL]. (2010)[2017-04-11]. http://www.satcm.gov.cn/web2010/zhengwugongkai/yizhengguanli/yiyuanguanli/2010-10-11/10176.html.
[6]
JAMIESON S. Likert scale:how to (ab)use them[J]. Med Educ, 2005, 38(12):1217-1218.
[7]
DONG D, SUN L H. Study of guideline for drug manufacturer on adverse drug reaction reporting and monitoring with Delphi method[J]. Chin J Pharmacov(�й�ҩ�ﾯ��), 2013, 10(9):523-526.
[8]
WANG C, SI Q. A study of data statistical processing method of Delphi method and its application [J]. J Inner Mongolia Finance Econ Coll (���ɹŲƾ���ѧѧ��), 2011, 9(4):97-101.
[9]
SUN J. Theoretical model for compatibility of medicinal property combination of traditional Chinese medicines [D]. Beijing:Beijing University of Chin Med, 2015.
[10]
WANG Y Y, ZHANG Q M, ZHANG Z B. The induction of syndrome factor and affecting target [J]. J Shandong Univ TCM(ɽ����ҽҩ��ѧѧ��), 2006, 30(1):6-7.
[11]
LINSTONE H A,TUROFF M. Delphi:a brief look backward and forward[J]. Technol Forecast Soc,2010, 78(9):1712-1719.
[12]
PING W W, TAN H Z. Progress of Delphi and its use in medicine [J]. Chin J Dis Control Prev (�л�����������־), 2003, 7(3):243-246.
[13]
GUO C Y, WANG Y Q, ZHANG M, et al. Thoughts and suggestions on the use of of Chinese patent medicines in pediatrics [J]. Chin Pharm J (�й�ҩѧ��־), 2017, 52(4):327-330.
[14]
GAO Y. Analysis and exploration of the reasons of drug withdrawal of Chinese traditional patent medicine [J]. Chin Modern Med (�й�����ҽҩ), 2012,19(25):177-178,184.
[15]
XU Y Q, HU J L. Statistical analysis of the utilization of Chinese medicine in out-patient electro-prescriptions of our hospital [J]. Chin J Drug Abuse Preven (�й�ҩ�����÷�����־), 2012, 18(3):157-159.
[16]
JIN R, WANG Y G, XUE C M, et al. The exploration on the creteria and compromise of prescription review of Chinese patent medicines ��:repeated medication[J]. Chin Hosp Pharm J(�й�ҽԺҩѧ��־),2015,35(7):565-570.
2017, Vol. 52 
